• Optimal curvilinear capsulorrhexis with a single dose, as assessed by the surgeon based on the tissue dyed and subsequently removed. [ Time Frame: During surgery ] [ Designated as safety issue: No ]
• Uncomplicated discharge [ Time Frame: Three months post-op ] [ Designated as safety issue: Yes ]

• Quality of stain [ Time Frame: during surgery ] [ Designated as safety issue: No ]
• Intra-ocular safety of DYME as measured by best corrected visual acuity, corneal endothelial cell count, intraocular pressure, presence/absence of retained dye, duration of surgery, and the absence of dye related adverse events [ Time Frame: 1-day and 1-week post-op ] [ Designated as safety issue: Yes ]
• Intra-ocular safety of DYME as measured by corneal endothelial cell count [ Time Frame: Three months post-op ] [ Designated as safety issue: Yes ]

The primary objective of this study is to test the hypothesis that DYME is safe and effective as a drug to facilitate continuous curvilinear capsulorhexis (CCC) by selectively staining the anterior capsule. Secondary objectives are to compare the safety and effectiveness of DYME to that of a smaller dose of the same API.

Inclusion Criteria:

• Have a cataract sufficiently opaque/mature/brunescent that, in the surgeon's assessment,a dye could facilitate surgery;
• Be aged at least 18 years old at the time of enrollment;
• Be in a medical condition suitable for cataract surgery;
• Able and willing to participate in study examinations and visit schedule; and
• Understand and freely consent to participate in the study.

Exclusion Criteria:

• In either eye, ocular infection or inflammation within the past 3 months;
• Known allergy to BBG 250;
• Uncontrolled intercurrent diseases including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia;
• Active treatment for cancer or systemic infection within the past month;
• Active treatment with systemic corticosteroids within the past month;
• Previous participation in this Study for the contralateral eye;
• Participation in another clinical trial involving an investigational therapeutic during the past 30 days or 5.5 half-lives (if applicable), whichever is longer;
• Unwillingness to participate in the study or inability to give informed consent; or
• Any medical condition that in the opinion of the Investigator may compromise the research subject's safety or ability to participate in the study.